SAN MATEO, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in two upcoming investor conferences. Cantor Global Healthcare Conference in New York on September 3, 2025, with a fireside chat at 1:35 p.m. ET / 10:35 a.m. PT; andH.C. Wainwright 27th Annual Global Investment Conference in New York on Se ...

Core Insights - OLAPLEX has announced its first acquisition of Purvala Bioscience, a Boston-based biotech company, marking a significant step in its commitment to product innovation after ten years since its launch [1][3] - Purvala focuses on developing bioinspired technologies for health and beauty, aiming to create high-performing molecules inspired by natural biological structures [2] - OLAPLEX's CEO emphasized the company's foundation on innovation and the potential to integrate Purvala's technologies to enhance its product offerings, particularly its bond-building technology [3] Company Overview - OLAPLEX, founded in 2014, revolutionized the hair care industry with its Complete Bond Technology™, which protects and strengthens hair during and after services [4] - The company has expanded its product line to include a full suite of hair health formulas, sold globally through various channels including professional and direct-to-consumer [4] - The acquisition of Purvala is expected to drive the next generation of science-backed product innovations, aligning with OLAPLEX's mission to deliver transformative results for stylists and customers [3][4]

Core Viewpoint - Eli Lilly's daily weight loss pill, orforglipron, has shown significant efficacy in helping patients with obesity and Type 2 diabetes lose weight in a late-stage trial, paving the way for global approval filings [1][5]. Group 1: Drug Efficacy and Trial Results - The highest dose of orforglipron resulted in an average weight loss of 10.5%, or 22.9 pounds, over 72 weeks, compared to a 2.2% weight loss in the placebo group [3]. - The drug also effectively lowered hemoglobin A1c levels, with most patients no longer meeting the criteria for Type 2 diabetes by the end of the study [4]. - The overall weight loss across all patients was 9.6%, regardless of discontinuations [3]. Group 2: Market Position and Competitive Advantage - Orforglipron is positioned as a needle-free alternative in the lucrative GLP-1 market, potentially increasing accessibility compared to existing weekly injections [2]. - The pill does not impose dietary restrictions, unlike a similar oral treatment from Novo Nordisk, enhancing its appeal [2]. Group 3: Side Effects and Patient Experience - The side effects were primarily gastrointestinal, with 23.1% experiencing vomiting and 36.4% and 27.4% reporting nausea and diarrhea, respectively [9]. - Approximately 20% of patients discontinued the pill for various reasons, similar to the placebo group, indicating a mix of factors beyond side effects [10]. Group 4: Future Outlook and Market Potential - Eli Lilly expects to launch the pill globally around this time next year, having gathered the necessary clinical trial data for regulatory approvals [5]. - The potential market is substantial, with over 100 million adults in the U.S. affected by obesity, highlighting the opportunity for orforglipron [11]. - Analysts suggest that the pill's easier manufacturing process and lack of dietary restrictions could make it a viable competitor in the obesity treatment space [15].

In ATTAIN-2, orforglipron met the primary and all key secondary endpoints, with compelling efficacy results and a safety profile consistent with injectable GLP-1 medicinesParticipants with obesity or overweight and type 2 diabetes, a population with increased difficulties losing weight, lost an average of 22.9 lbs (10.5%) on the highest dose, with A1C reduced by an average of 1.8%INDIANAPOLIS, Aug. 26, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the P ...

COLUMBUS, Ohio, Aug. 26, 2025 /PRNewswire/ -- Designer Brands Inc. (NYSE: DBI), one of the world's largest designers, producers and retailers of footwear and accessories, announced the Company will issue its second quarter 2025 earnings on September 9, 2025. Management will host a conference call to discuss the results at 8:30 am E.T. A press release detailing the Company's results will be issued prior to the call.Investors and analysts interested in participating in the call are invited to dial 888-317-600 ...

THE WOODLANDS, Texas, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Ring Energy, Inc. (NYSE American: REI) (“Ring” or the “Company”) today reported its debt reduction target for the third quarter of 2025 and the change in ownership status of a previous large stockholder. Ring Energy has established a debt reduction target of approximately $18 million for the third quarter of 2025. The Company anticipates it will have approximately $430 million in borrowings outstanding on its credit facility as of September 30, 2025, d ...

D-Wave (NYSE: QBTS ) is the first company to achieve a quantum annealing system, and its shares have gone through the roof since the IPO. Since going public via SPAC in 2022, QBTS stock has exploded. It rocketed from sub-$1Hi, I'm a dedicated Stock Analyst aiming to identify clear winners in the market. I'm here to help others make informed investment decisions by delivering clear, insightful, and easy-to-understand financial content. My work has been featured on several leading platforms, including Yahoo, ...

This photograph shows the logo of the logo of SentinelOne during the 17th edition of the "InCyber" Forum, an international cyber security event, at the Grand Palais in Lille, northern France, on April 1, 2025. The forum, which brings together the entire cybersecurity and "trusted digital" ecosystem, runs until April 3, 2025. (Photo by Sameer Al-DOUMY / AFP) (Photo by SAMEER AL-DOUMY/AFP via Getty Images)AFP via Getty ImagesSentinelOne (NYSE:S) is scheduled to report its Q2 2026 earnings on Thursday, August ...

POLAND - 2025/03/07: In this photo illustration, the Coty Inc company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesMerely a year ago, Coty Inc. stock (NYSE: COTY) was priced around $10, but it now hovers close to $4, having declined more than 50% from its peak. This significant drop is indicative of more than just market fluctuations—it highlights the pressures that are heavily impacting one ...

Core Viewpoint - The dismissal of Federal Reserve governor Lisa Cook by President Trump over alleged mortgage fraud has led to market volatility, raising concerns about the independence of the Federal Reserve and its implications for monetary policy [1][6][7]. Market Reactions - Stock markets and bonds experienced a sell-off following the announcement, with US government bond yields rising, particularly the 30-year bond which surpassed 5.6%, nearing a 27-year high [3]. - The dollar initially dropped nearly 0.4% but largely reversed this decline, while gold prices spiked by 1% and maintained most of the overnight gain [4]. Federal Reserve Implications - Cook's potential dismissal would create another vacancy on the Federal Reserve board, which Trump is expected to fill with an economist favoring interest rate cuts [3]. - The current situation raises concerns about "intensifying fiscal dominance risks" within the Federal Reserve, as noted by Deutsche Bank forex strategist George Saravelos [7]. Independence of the Federal Reserve - Analysts suggest that Trump's actions may undermine confidence in the Federal Reserve's independence, which is crucial for maintaining transparent and rules-based capital markets [6]. - The attempted removal of Cook is described as unprecedented, potentially signaling the end of central bank independence in the US [7][8].